Exclusive Summary

• Disruptive Cost-Effectiveness: As a National Class 1 Innovative Drug, it offers proprietary IP and validated efficacy at a generic-tier price point (~$28 USD/vial), creating a massive competitive edge against expensive Western originators.
• De-risked Asset: With Phase III clinical trials completed, the drug presents minimal R&D risk for partners, allowing for a streamlined pathway to regulatory approval and commercialization in target markets.
• Ideal for Emerging Markets: The anticipated low price coupled with flexible Licensing/Tech Transfer models makes it perfectly suited for price-sensitive markets (LATAM, SEA, MENA) seeking accessible innovation.

Asset Materials

Contact Us for Full Materials